AA
IMVT icon

ABC Arbitrage’s Immunovant IMVT Stock Holding History

ABC Arbitrage’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14,639
Closed -$236K – 365
2025
Q3 		$236K Buy
+14,639
New +$237K 0.02% 187
2025
Q2 		– Sell
-37,449
Closed -$640K – 234
2025
Q1 		$640K Buy
37,449
+7,810
+26% +$163K 0.12% 143
2024
Q4 		$734K Buy
+29,639
New +$841K 0.11% 149

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ABC Arbitrage's IMVT Position: Q4 2025 in Review

ABC Arbitrage sold out of Immunovant (IMVT) in Q4 2025, closing a stake of 14,639 shares — an estimated $236K sold.

ABC Arbitrage first reported a position in IMVT in Q4 2024 and held it in 3 quarters. The position peaked at $734K in Q4 2024. 197 funds tracked by Wall St. Rank hold IMVT as of Q4 2025.

  • ABC Arbitrage reported no remaining Immunovant position as of Q4 2025 after selling out during the quarter.
  • ABC Arbitrage sold 14,639 Immunovant shares in Q4 2025, an estimated $236K.
  • ABC Arbitrage first reported a position in Immunovant in Q4 2024 and held it in 3 quarters.
  • ABC Arbitrage's Immunovant position peaked at $734K in Q4 2024.
  • 197 funds tracked by Wall St. Rank held Immunovant as of Q4 2025.

Based on ABC Arbitrage's 13F filing for Q4 2025, filed 4 Feb 2026.